Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings for the next-generation ...

Complex DNA-breakage events such as chromosomal shattering ... such as epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1 (FGFR1), are validated drug targets for ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

Somewhere in the body of a patient, a small clump of cells, growing undetected, has begun to form a tumor. It has yet to ...